Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial

Metabolism: Clinical and Experimental

Volumn 57, Issue 11, 2008, Pages 1563-1569

  Zimering, Mark B ^a,b   Anderson, Robert J ^a,c   Luo, Ping ^a   Moritz, Thomas E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FUROSEMIDE; GABAPENTIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; STATIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISPANIC; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; SENSITIVITY AND SPECIFICITY; WAIST HIP RATIO;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS;

EID: 53649096106     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.06.012     Document Type: Article

References (35)

1. Gospodarowicz D., Ferrara N., Schweigerer L., and Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8 (1987) 95-114
2. Esch F., Baird A., Ling N., Ueno N., Hill F., Denoroy L., et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Nat Acad Sci U S A 19 (1985) 6507-6511
3. Hasdai D., Barak V., Leibovitz E., Herz I., Sclarovsky S., Eldar M., et al. Serum basic fibroblast growth factor levels in patients with ischemic heart disease. Int J Cardiol 59 (1997) 133-138
4. Katinioti A.A., Tousoulis D., Economou E., Stefanadis C., Trikas A., Tentolouris C., et al. Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina. Int J Cardiol 84 (2002) 195-199
5. Kraemer R., Pomerantz K.B., Joseph-Silverstein J., and Hajjar D.P. Induction of basic fibroblast growth factor mRNA and protein synthesis in smooth muscle cells by cholesteryl ester enrichment and 25-hydroxycholesterol. J Biol Chem 268 (1993) 8040-8045
6. Cucina A., Scavo M.P., Muzzioli L., Coluccia P., Ceccarini S., Fuso A., et al. High density lipoproteins downregulate basic fibroblast growth factor production and release in minimally oxidated-LDL treated smooth muscle cells. Atherosclerosis 189 (2006) 303-309
7. Abraira C., Duckworth W., McCarren M., Emanuele N., Arca D., Reda D., et al. Design of the cooperative study of glycemic control and complications in diabetes mellitus type 2. J Diabet Complications 17 (2003) 314-322
8. Schweigerer L., Neufeld G., Friedman J., Abraham J.A., Fiddes J.C., and Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325 (1987) 257-259
9. Zimering M.B., and Eng J. Increased basic fibroblast growth factor-like substance in plasma from a subset of middle-aged or elderly male diabetic patients with microalbuminuria or proteinuria. J Clin Endocrinol Metab 81 (1996) 4446-4452
10. Zimering M.B. Effect of intravenous bisphosphonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sci 70 (2002) 1-14
11. Larsson A., Skoldenberg E., and Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 5 (2002) 107-110
12. Dirix L.Y., Vermeulen P.B., Pawinski A., Prové A., Benoy I., De Pooter C., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76 (1997) 238-243
13. Tabone M.D., Landman-Parker J., Arcil B., Coudert M.C., Gerota I., Benbunan M., et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?. Clin Cancer Res 7 (2001) 538-543
14. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
15. Kaneko T., Fujii S., Matsumoto A., Goto D., Ishimori N., Watano K., et al. Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. Arterioscler Thromb Vasc Biol 22 (2002) 855-860
16. Sahni A., Sahni S.K., Simpson-Haidaris P.J., and Francis C.W. Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells. J Thromb Haemost 2 (2004) 1629-1636
17. Keber I., and Keber D. Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis. Haemostasis 22 (1992) 187-194
18. Thogersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
19. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., and deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20 (2000) 2019-2023
20. Lutsey P.L., Cushman M., Steffen L.M., Green D., Barr R.G., Herrington D., et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost 4 (2006) 2629-2635
21. Frist S.T., Taylor Jr. H.A., Kirk K.A., Grammer J.R., Li X.N., Grenett H.E., et al. Expression of PAI-1, t-PA and u-PA in cultured human umbilical vein endothelial cells derived from racial groups. Thromb Res 77 (1995) 279-290
22. Alessi M.C., Bastelica D., Morange P., Berthet B., Leduc I., Verdier M., et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49 (2000) 1374-1380
23. Flugelman M.Y., Virmani R., Correa R., Yu Z.X., Farb A., Leon M.B., et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 88 (1993) 2493-2500
24. Mydlo J.H., Kral J.G., and Macchia R.J. Differences in prostate and adipose tissue basic fibroblast growth factor: analysis of preliminary results. Urology 50 (1997) 472-478
25. Mydlo J.H., Kral J.G., and Macchia R.J. Preliminary results comparing the recovery of basic fibroblast growth factor (FGF-2) in adipose tissue and benign and malignant renal tissue. J Urol 159 (1998) 2159-2163
26. Teichert-Kuliszewska K., Hamilton B.S., Deitel M., and Roncari D.A. Augmented production of heparin-binding mitogenic proteins by preadipocytes from massively obese persons. J Clin Invest 90 (1992) 1226-1231
27. Fain J.N. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74 (2006) 443-477
28. Liuzzo J.P., Petanceska S.S., Moscatelli D., and Devi L.A. Inflammatory mediators regulate cathepsin S in macrophages and microglia: a role in attenuating heparan sulfate interactions. Mol Med 5 (1999) 320-333
29. Itoh H., Mukoyama M., Pratt R., Gibbons G., and Dzau V. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91 (1993) 2268-2274
30. Alderman M.H., Cohen H.W., Sealey J.E., and Laragh J.H. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 17 (2004) 1-7
31. Holland O.B., von Kuhnert L., Campbell W.B., and Anderson R.J. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension 5 (1983) 235-239
32. Coppack S.W. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60 (2001) 349-356
33. Samaniego F., Markham P.D., Gendelman R., Gallo R.C., and Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. J Immunol 158 (1997) 1887-1894
34. Kurata A., Nishizawa H., Kihara S., Maeda N., Sonoda M., Okada T., et al. Blockade of angiotensin II type 1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 70 (2006) 1717-1724
35. Hughes S.E., Crossman D., and Hall P.A. Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res. 27 (1993) 1214-1219